5 hours Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?The Motley Fool
The market didn’t appreciate Amgen’s (NASDAQ: AMGN) latest clinical data update, with the biopharma’s shares falling more than 12% at one point on Nov. 26 from the previous day’s close, though they recovered to close just 4.7% down for the day.
And, wi…
Amgen (AMGN) · Eli Lilly (LLY) · Nasdaq 100
X